AU635401B2 - Improvements in or relating to organic compounds - Google Patents

Improvements in or relating to organic compounds

Info

Publication number
AU635401B2
AU635401B2 AU72909/91A AU7290991A AU635401B2 AU 635401 B2 AU635401 B2 AU 635401B2 AU 72909/91 A AU72909/91 A AU 72909/91A AU 7290991 A AU7290991 A AU 7290991A AU 635401 B2 AU635401 B2 AU 635401B2
Authority
AU
Australia
Prior art keywords
antibodies
relating
organic compounds
paticularly
immunoconjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired, expires
Application number
AU72909/91A
Other languages
English (en)
Other versions
AU7290991A (en
Inventor
Arne Nalpon Akbar
Peter Lloyd Amlot
Salvatore Cammisuli
Gunther Heinrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
University College London
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26296798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU635401(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909005962A external-priority patent/GB9005962D0/en
Priority claimed from GB909019323A external-priority patent/GB9019323D0/en
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of AU7290991A publication Critical patent/AU7290991A/en
Application granted granted Critical
Publication of AU635401B2 publication Critical patent/AU635401B2/en
Assigned to NOVARTIS AG, ROYAL FREE HOSPITAL SCHOOL OF MEDICINE reassignment NOVARTIS AG Request to Amend Deed and Register Assignors: ROYAL FREE HOSPITAL SCHOOL OF MEDICINE, SANDOZ LTD.
Assigned to UNIVERSITY COLLEGE LONDON, NOVARTIS AG reassignment UNIVERSITY COLLEGE LONDON Request to Amend Deed and Register Assignors: NOVARTIS AG, ROYAL FREE HOSPITAL SCHOOL OF MEDICINE
Adjusted expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU72909/91A 1990-03-16 1991-03-14 Improvements in or relating to organic compounds Expired AU635401B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9005962 1990-03-16
GB909005962A GB9005962D0 (en) 1990-03-16 1990-03-16 Improvements in or relating to organic compounds
GB909019323A GB9019323D0 (en) 1990-09-05 1990-09-05 Improvements relating to immunosuppression
GB9019323 1990-09-05

Publications (2)

Publication Number Publication Date
AU7290991A AU7290991A (en) 1991-09-19
AU635401B2 true AU635401B2 (en) 1993-03-18

Family

ID=26296798

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72909/91A Expired AU635401B2 (en) 1990-03-16 1991-03-14 Improvements in or relating to organic compounds

Country Status (23)

Country Link
US (2) US6521230B1 (enExample)
EP (1) EP0449769B1 (enExample)
JP (1) JP2585475B2 (enExample)
AT (1) ATE98655T1 (enExample)
AU (1) AU635401B2 (enExample)
CA (1) CA2038279C (enExample)
CY (1) CY1977A (enExample)
DE (2) DE69100768T2 (enExample)
DK (1) DK0449769T3 (enExample)
ES (1) ES2061216T3 (enExample)
FI (3) FI103131B (enExample)
HK (1) HK53797A (enExample)
HU (2) HUT60768A (enExample)
IE (1) IE65062B1 (enExample)
IL (1) IL97545A (enExample)
LU (1) LU90383I2 (enExample)
MY (1) MY106161A (enExample)
NL (1) NL990008I2 (enExample)
NZ (1) NZ237434A (enExample)
PL (1) PL170321B1 (enExample)
PT (1) PT97034B (enExample)
SA (1) SA92120358B1 (enExample)
TW (1) TW213486B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
JPH07509444A (ja) * 1991-11-26 1995-10-19 アルカーメス・インコーポレーテツド トランスフェリンセレプター特異的抗体−神経薬又は診断薬複合体の製造法
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
US6106834A (en) 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
CA2298491C (en) 1997-07-25 2009-10-06 Nichia Chemical Industries, Ltd. Nitride semiconductor device
AUPP221098A0 (en) * 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
JP3973360B2 (ja) * 1998-07-27 2007-09-12 ノバルティス アクチエンゲゼルシャフト 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子
US6406695B1 (en) 1998-10-30 2002-06-18 University Of Miami Treatment of hepatitis C by administration of anti-IL-2 receptor monoclonal antibody
WO2000025816A1 (en) * 1998-10-30 2000-05-11 The University Of Miami Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound
GB9825632D0 (en) 1998-11-23 1999-01-13 Novartis Ag Organic compounds
FR2793691B1 (fr) * 1999-05-21 2003-10-03 Hippocampe Utilisation d'anticorps reconnaissant le recepteur de l'interleukine-2 dans la prevention et/ou le traitement des infections par les virus du sida
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
HUP0400986A3 (en) * 2001-04-06 2012-09-28 Univ Bristol Use of cd25 binding molecules in steroid-resistant patients
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
NZ540555A (en) 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
WO2005037867A1 (en) * 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
ATE509954T1 (de) 2005-12-30 2011-06-15 Merck Patent Gmbh Anti-cd19-antikörper mit reduzierter immunogenität
RU2540013C2 (ru) 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
CN102027017A (zh) 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
JP5604311B2 (ja) 2008-03-13 2014-10-08 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
HRP20240920T1 (hr) 2009-10-26 2024-10-11 F. Hoffmann - La Roche Ag Postupak za proizvodnju glikoziliranog imunoglobulina
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2791169B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
BR112017011111A2 (pt) 2014-11-25 2017-12-26 Adc Therapeutics Sa conjugados de pirrolobenzodiazepina-anticorpo
US9993452B2 (en) 2014-12-05 2018-06-12 Vireo Systems, Inc. Compositions and methods for treatment of inflammation
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
EP3612236A1 (en) 2017-04-20 2020-02-26 ADC Therapeutics SA Combination therapy with an anti-cd25 antibody-drug conjugate
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
GB201811364D0 (en) 2018-07-11 2018-08-29 Adc Therapeutics Sa Combination therapy
ES3037019T3 (en) * 2019-06-10 2025-09-26 Shandong Boan Biotechnology Co Ltd Anti-cd25 antibody and application thereof
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US20230056336A1 (en) 2021-04-15 2023-02-23 Kyverna Therapeutics, Inc. Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CN114957473B (zh) * 2022-04-25 2023-05-16 苏州旭光科星抗体生物科技有限公司 一种对可溶性cd25蛋白含量检测的酶联免疫检测试剂盒
WO2024006961A1 (en) 2022-07-01 2024-01-04 Neoleukin Therapeutics, Inc. Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0235805A2 (en) * 1986-03-04 1987-09-09 The Royal Free Hospital School Of Medicine Improvements relating to immunosuppression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188941B (en) 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
DE3850750T2 (de) * 1987-12-02 1994-12-22 Becton Dickinson Co Verfahren zur Verhütung von GVHD.
JPH02503867A (ja) * 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
DE3815472A1 (de) 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0235805A2 (en) * 1986-03-04 1987-09-09 The Royal Free Hospital School Of Medicine Improvements relating to immunosuppression

Also Published As

Publication number Publication date
JPH04316600A (ja) 1992-11-06
FI981799L (fi) 1998-08-21
AU7290991A (en) 1991-09-19
FI104047B1 (fi) 1999-11-15
FI19991788A7 (fi) 1999-08-23
EP0449769B1 (en) 1993-12-15
US6521230B1 (en) 2003-02-18
DE69100768T2 (de) 1994-05-11
LU90383I2 (fr) 1999-06-07
HUT60768A (en) 1992-10-28
DK0449769T3 (da) 1994-02-21
PT97034B (pt) 1998-07-31
FI103131B1 (fi) 1999-04-30
FI911275A0 (fi) 1991-03-14
FI981799A0 (fi) 1998-08-21
HK53797A (en) 1997-05-02
CA2038279C (en) 1999-03-09
ES2061216T3 (es) 1994-12-01
DE19975033I2 (de) 2007-01-04
ATE98655T1 (de) 1994-01-15
PT97034A (pt) 1991-10-31
IE65062B1 (en) 1995-10-04
NL990008I2 (nl) 1999-10-01
FI911275L (fi) 1991-09-17
HU211885A9 (en) 1995-12-28
IL97545A0 (en) 1992-06-21
PL289436A1 (en) 1992-02-24
TW213486B (enExample) 1993-09-21
FI103131B (fi) 1999-04-30
FI19991788L (fi) 1999-08-23
US6383487B1 (en) 2002-05-07
NZ237434A (en) 1992-08-26
CA2038279A1 (en) 1991-09-17
IE910867A1 (en) 1991-09-25
NL990008I1 (nl) 1999-06-01
HU910761D0 (en) 1991-09-30
FI104047B (fi) 1999-11-15
JP2585475B2 (ja) 1997-02-26
IL97545A (en) 2000-06-29
MY106161A (en) 1995-03-31
EP0449769A1 (en) 1991-10-02
PL170321B1 (pl) 1996-11-29
SA92120358B1 (ar) 2004-01-25
DE69100768D1 (de) 1994-01-27
CY1977A (en) 1997-09-05

Similar Documents

Publication Publication Date Title
AU635401B2 (en) Improvements in or relating to organic compounds
ATE208820T1 (de) Humanisierte antikoerper
WO1990010709A3 (en) Monoclonal antibodies for metallic cations on small molecules
DK0626447T3 (da) Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen
GB2246781A (en) CD3 specific recombinant antibody
EP0499176A3 (en) Monoclonal antibodies against human pancreatic islet cells
EP0257778A3 (en) Apolipoprotein b-specific monoclonal antibodies produced by two novel hybridomas
GB0309126D0 (en) Clostridium difficile focussed antibodies
DE3582386D1 (de) Menschlicher, monoklonaler antikoerper und seine herstellung.
EP0338395A3 (en) Monoclonal antibodies to pseudomonas aeruginosa, their production and use
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof
JPS6463374A (en) Human monoclonal antibody, antibody-forming cell, antibody-forming hybridoma and production of antibody
MY104917A (en) Monoclonal antibodies and methods for diagnosis of phytophora infection
AU8264491A (en) Monoclonal antibodies to leptosphaeria
IL98636A0 (en) Monoclonal antibodies to mycosphaerella species,their production and compositions containing them